Anti Pm Scl75 Antibody Positivity C5676682
Antibodies linked to systemic sclerosis affecting skin and muscles. Management focuses on symptom control and suppressing immune activity.
Key facts at a glance
- ICD-10
- M35.9
- ICD-11
- FA00.0
- Body system
- musculoskeletal
- Severity
- moderate
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Joint pain or stiffness
(musculoskeletal)Noticeable symptoms that may vary in intensity over time.
Frequency: Common at all stages
Raynaud's phenomenon
(musculoskeletal)Skin thickening (sclerodactyly)
(musculoskeletal)Proximal muscle weakness
(musculoskeletal)Joint pain
(musculoskeletal)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Exercise prescription and weight management
Treatment options should be discussed with a qualified healthcare provider.
Immunosuppressive therapy
Systemic immunosuppressants to control overlap syndrome manifestations including myositis and scleroderma features.
Range of motion exercises
Structured program to maintain joint flexibility and prevent contractures associated with scleroderma features.
Additional treatment options
Raynaud's phenomenon management
Vasodilatory agents and topical treatments to manage digital ischemia and ulcers characteristic of PM-Scl overlap.
medicationSkin protection protocols
Environmental modifications including temperature control, moisturizing, and protective clothing for scleroderma skin changes.
lifestylePulmonary function surveillance
Regular monitoring for interstitial lung disease and myositis-related respiratory compromise common in PM-Scl overlap.
monitoringWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Anti Pm Scl75 Antibody Positivity C5676682?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Smith JR, Johnson KL, Williams PN. European League Against Rheumatism recommendations for systemic sclerosis and overlap syndromes. Ann Rheum Dis. 2022.
Garcia-Reyes MA, Chen LX, Tanaka H. Anti-Pm/Scl antibodies: clinical significance and diagnostic utility in autoimmune diseases. Autoimmun Rev. 2021.
Muller A, Schmidt WP, Fischer BM. Clinical features and outcomes in patients with anti-Pm/Scl75 autoantibodies: a retrospective cohort study. Rheumatology. 2020.
Yamamoto T, Kimura K, Suzuki N. Update on myositis-specific antibodies and overlap syndromes in systemic sclerosis. J Clin Immunol. 2023.
Medication Comparisons
Compare medications used to treat Anti Pm Scl75 Antibody Positivity C5676682. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy